{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:06:58Z","timestamp":1790795218882,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T00:00:00Z","timestamp":1542153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.ahj.2018.09.011","type":"journal-article","created":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T18:15:18Z","timestamp":1538244918000},"page":"80-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":289,"special_numbering":"C","title":["Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study"],"prefix":"10.1016","volume":"206","author":[{"given":"Aruna D.","family":"Pradhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina P.","family":"Paynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Everett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Glynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Amarenco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall","family":"Elam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G.","family":"Nordestgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Fruchart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2018.09.011_bb0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00125-003-1111-y","article-title":"Diabetic dyslipidaemia: from basic research to clinical practice","volume":"46","author":"Taskinen","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2018.09.011_bb0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1517\/14656566.2010.502529","article-title":"Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies","volume":"12","author":"Chan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ahj.2018.09.011_bb0015","series-title":"Clinical Lipidology, Companion to Braunwald's Heart Disease","first-page":"401","article-title":"Special Populations: Diabetes and Metabolic Syndrome","author":"Reyes-Soffer","year":"2014"},{"key":"10.1016\/j.ahj.2018.09.011_bb0020","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.09.011_bb0025","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000381304","article-title":"Are elevated serum triglycerides really a risk factor for coronary artery disease?","volume":"131","author":"Reiner","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2018.09.011_bb0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1161\/CIRCULATIONAHA.113.002529","article-title":"Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries","volume":"129","author":"Sacks","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0035","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacc.2012.11.002","article-title":"The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology","volume":"60","author":"Laslett","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0040","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S2213-8587(14)70102-0","article-title":"Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: a comparative risk assessment","volume":"2","author":"Global Burden of Metabolic Risk Factors for Chronic Diseases C","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0045","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0050","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","article-title":"Lipoprotein lipase: from gene to obesity","volume":"297","author":"Wang","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ahj.2018.09.011_bb0055","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0060","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1161\/01.ATV.0000143859.75035.5a","article-title":"Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy","volume":"24","author":"Proctor","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrcardio.2017.31","article-title":"Hypertriglyceridaemia and risk of coronary artery disease","volume":"14","author":"Reiner","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0070","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/01.RES.33.6.633","article-title":"A proposal linking atherogenesis to the interaction of endothelial lipoprotein lipase with triglyceride-rich lipoproteins","volume":"33","author":"Zilversmit","year":"1973","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2018.09.011_bb0075","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0080","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/eurheartj\/ehu500","article-title":"Triglycerides on the rise: should we swap seats on the seesaw?","volume":"36","author":"Libby","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.09.011_bb0085","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Emerging Risk Factors C","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.09.011_bb0090","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0095","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0100","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease","volume":"377","author":"Group HTRC","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0110","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Investigators A-H","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0115","first-page":"1943","article-title":"Niacin for reduction of cardiovascular risk","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0125","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/eurheartj\/eht571","article-title":"Mendelian randomization of blood lipids for coronary heart disease","volume":"36","author":"Holmes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.09.011_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11886-017-0940-0","article-title":"HDL cholesterol metabolism and the risk of CHD: new insights from human genetics","volume":"19","author":"Vitali","year":"2017","journal-title":"Curr Cardiol Rep"},{"issue":"4","key":"10.1016\/j.ahj.2018.09.011_bb0135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCRESAHA.115.306398","article-title":"Surprises from genetic analyses of lipid risk factors for atherosclerosis","volume":"118","author":"Musunuru","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2018.09.011_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.atherosclerosis.2017.10.025","article-title":"Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism","volume":"267","author":"Wolska","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.09.011_bb0145","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.gene.2016.07.070","article-title":"Apolipoprotein A5 fifteen years anniversary: Lessons from genetic epidemiology","volume":"592","author":"Hubacek","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.ahj.2018.09.011_bb0150","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ahj.2018.09.011_bb0155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Tg, Hdl Working Group of the Exome Sequencing Project NHL","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0165","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/j.jacc.2015.08.866","article-title":"Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: the multi-ethnic bioimage study","volume":"66","author":"Natarajan","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0170","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature13917","article-title":"Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction","volume":"518","author":"Do","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2018.09.011_bb0175","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(10)60545-4","article-title":"Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies","volume":"375","author":"Triglyceride Coronary Disease Genetics C","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0180","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0185","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ahj.2018.09.011_bb0195","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/ng.784","article-title":"Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease","volume":"43","author":"Schunkert","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0200","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/ng.2797","article-title":"Discovery and refinement of loci associated with lipid levels","volume":"45","author":"Willer","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0205","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0210","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/eurheartj\/ehs431","article-title":"Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction","volume":"34","author":"Jorgensen","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2018.09.011_bb0215","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0220","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0225","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1373\/clinchem.2013.219881","article-title":"Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study","volume":"60","author":"Thomsen","year":"2014","journal-title":"Clin Chem"},{"key":"10.1016\/j.ahj.2018.09.011_bb0230","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.amjcard.2016.04.004","article-title":"Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease","volume":"118","author":"Budoff","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11883-017-0667-9","article-title":"Genetics of Triglycerides and the Risk of Atherosclerosis","volume":"19","author":"Dron","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.ahj.2018.09.011_bb0240","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.09.011_bb0250","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.metabol.2010.12.003","article-title":"Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans","volume":"60","author":"Perreault","year":"2011","journal-title":"Metabolism"},{"key":"10.1016\/j.ahj.2018.09.011_bb0255","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0260","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1002\/j.1460-2075.1996.tb00918.x","article-title":"PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene","volume":"15","author":"Schoonjans","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.ahj.2018.09.011_bb0265","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmet.2014.02.002","article-title":"Integrated physiology and systems biology of PPARalpha","volume":"3","author":"Kersten","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.ahj.2018.09.011_bb0270","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2018.09.011_bb0275","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Group AS","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0280","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0285","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.09.011_bb0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/ncpendmet0397","article-title":"Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors","volume":"3","author":"Gervois","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.ahj.2018.09.011_bb0295","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0300","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1016\/j.bmcl.2007.05.066","article-title":"Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists","volume":"17","author":"Yamazaki","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ahj.2018.09.011_bb0305","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2018.03.135","article-title":"Molecular association model of PPARalpha and its new specific and efficient ligand, pemafibrate: structural basis for SPPARMalpha","volume":"499","author":"Yamamoto","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.ahj.2018.09.011_bb0310","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.5551\/jat.ER39693","article-title":"A novel selective PPARalpha modulator (SPPARMalpha), K-877 (Pemafibrate), attenuates postprandial hypertriglyceridemia in mice","volume":"25","author":"Sairyo","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ahj.2018.09.011_bb0315","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.03.003","article-title":"The novel selective PPARalpha modulator (SPPARMalpha) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis","volume":"249","author":"Hennuyer","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.09.011_bb0320","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","article-title":"Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia","volume":"261","author":"Arai","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ahj.2018.09.011_bb0325","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/ATVBAHA.113.302926","article-title":"Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST)","volume":"34","author":"Davidson","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0330","doi-asserted-by":"crossref","first-page":"676","DOI":"10.5551\/jat.27425","article-title":"Determinants of bezafibrate-induced improvements in LDL cholesterol in dyslipidemic patients with diabetes","volume":"22","author":"Hirose","year":"2015","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.ahj.2018.09.011_bb0335","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1172\/JCI106896","article-title":"Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man","volume":"51","author":"Wilson","year":"1972","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2018.09.011_bb0340","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI108229","article-title":"Conversion of very low density lipoprotein to low density lipoprotein. A metabolic study of apolipoprotein B kinetics in human subjects","volume":"56","author":"Sigurdsson","year":"1975","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2018.09.011_bb0345","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1172\/JCI111739","article-title":"Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss","volume":"75","author":"Ginsberg","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ahj.2018.09.011_bb0350","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ahj.2018.09.011_bb0355","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ahj.2018.09.011_bb0360","doi-asserted-by":"crossref","first-page":"538","DOI":"10.2337\/dc17-1589","article-title":"Effects of pemafibrate, a novel selective PPARa modulator, on lipid and glucose metbolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controled, phase 3 trial","volume":"41","author":"Araki","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2018.09.011_bb0365","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ahj.2018.09.011_bb0370","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.2337\/dc11-1811","article-title":"Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants","volume":"35","author":"Mychaleckyj","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ahj.2018.09.011_bb0375","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.09.011_bb0380","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0385","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"Hicks","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2018.09.011_bb0390","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","article-title":"An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Sacco","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.ahj.2018.09.011_bb0395","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.ahj.2018.09.011_bb0400","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1023\/A:1025822717910","article-title":"Adaptive test for testing the difference in survival distributions","volume":"9","author":"Peckova","year":"2003","journal-title":"Lifetime Data Anal"},{"key":"10.1016\/j.ahj.2018.09.011_bb0405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1740774510369019","article-title":"A general inefficacy interim monitoring rule for randomized clinical trials","volume":"7","author":"Freidlin","year":"2010","journal-title":"Clin Trials"},{"key":"10.1016\/j.ahj.2018.09.011_bb0410","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0415","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0420","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2018.09.011_bb0425","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2018.09.011_bb0430","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"Bezafibrate Infarction Prevention Study and the BIP Study Group","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2018.09.011_bb0435","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318302801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870318302801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:01:55Z","timestamp":1757570515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870318302801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":87,"alternative-id":["S0002870318302801"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2018.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}